MARIOTTINI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 868
EU - Europa 686
AS - Asia 322
SA - Sud America 2
OC - Oceania 1
Totale 1.879
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 865
IT - Italia 211
IE - Irlanda 183
HK - Hong Kong 121
SE - Svezia 99
CN - Cina 90
PL - Polonia 76
JO - Giordania 36
RU - Federazione Russa 33
SG - Singapore 27
IR - Iran 16
DE - Germania 15
IN - India 14
CH - Svizzera 12
GB - Regno Unito 11
ES - Italia 10
FI - Finlandia 10
FR - Francia 10
TR - Turchia 7
UA - Ucraina 7
KR - Corea 5
VN - Vietnam 4
CA - Canada 3
GR - Grecia 3
BR - Brasile 2
LT - Lituania 2
NL - Olanda 2
SA - Arabia Saudita 2
AT - Austria 1
AU - Australia 1
LV - Lettonia 1
Totale 1.879
Salva come PNG Salva come JPEG
Città #
Dublin 183
Chandler 112
Fairfield 99
Hong Kong 84
Ashburn 80
Warsaw 74
Milan 59
Kent 52
Florence 48
Altamura 45
Lawrence 45
Beijing 40
Seattle 34
Moscow 33
Cambridge 32
Woodbridge 32
Princeton 31
Wilmington 31
Boston 27
Buffalo 24
Houston 23
Singapore 20
Shanghai 19
West Jordan 13
Bern 11
Barcelona 10
Dearborn 10
Hamburg 9
Medford 9
Rome 9
Lappeenranta 8
San Diego 8
Ann Arbor 7
Istanbul 7
Norwalk 7
Pune 7
New York 6
Tehran 6
Seoul 5
Chennai 4
Dong Ket 4
Falls Church 4
Spring Hill 4
Thessaloniki 3
Casoria 2
Chengdu 2
Chivasso 2
Cincinnati 2
Eastbourne 2
Forlì 2
Forney 2
Gdansk 2
Hangzhou 2
Hefei 2
Helsinki 2
Hillsboro 2
Kunming 2
Legnaro 2
London 2
Lyon 2
Mumbai 2
Redmond 2
Riyadh 2
San Giorgio a Cremano 2
Taranto 2
Toronto 2
Vilnius 2
Americana 1
Amsterdam 1
Andover 1
Arezzo 1
Audun-le-Roman 1
Boardman 1
Bremen 1
Brisbane 1
Campi Bisenzio 1
Carate Brianza 1
Castelliri 1
Castle Rock 1
Frankfurt am Main 1
Fuzhou 1
Hebei 1
Jinan 1
Kilburn 1
Les Paccots 1
Los Angeles 1
Merate 1
Montreal 1
Nanjing 1
Naples 1
New Bedfont 1
New Delhi 1
Olbia 1
Palmetto 1
Paris 1
Pavia 1
Pescia 1
Riga 1
Scandicci 1
Sheffield 1
Totale 1.457
Salva come PNG Salva come JPEG
Nome #
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 109
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis. 103
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 99
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 85
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 82
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 68
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 62
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 57
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 51
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 48
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 46
Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis- A Real World Experience 46
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 43
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 43
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 41
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 41
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 40
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 39
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 39
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 38
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 37
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 37
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 36
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 35
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 35
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 35
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 33
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 33
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 33
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis 33
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 32
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 31
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 30
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series 27
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status 26
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 24
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 22
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 21
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 21
COVID-19 in patients with aggressive MS treated with aHSCT: a multi-center study 20
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 20
Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management 20
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 18
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 18
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 15
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 13
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? 11
Antibody-mediated cell depletion therapies in multiple sclerosis 11
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis 10
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 10
Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances 10
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 9
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study 6
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 5
Totale 1.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.677
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.677
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020213 4 2 3 11 30 11 27 26 29 32 30 8
2020/2021152 15 15 6 30 7 8 13 14 14 16 6 8
2021/2022205 2 15 8 9 2 8 5 33 18 7 32 66
2022/2023683 44 112 45 34 35 126 104 36 102 1 27 17
2023/2024631 16 75 69 35 53 47 24 106 29 66 77 34
2024/202540 40 0 0 0 0 0 0 0 0 0 0 0
Totale 1.957